GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » Cyclically Adjusted PB Ratio

Synergy Pharmaceuticals (FRA:S90) Cyclically Adjusted PB Ratio : (As of May. 20, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Synergy Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Synergy Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Synergy Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Synergy Pharmaceuticals Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Synergy Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Synergy Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synergy Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synergy Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Synergy Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Synergy Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Synergy Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2018 is calculated as:

For example, Synergy Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2018 was:

Adj_Book=Book Value per Share/CPI of Sep. 2018 (Change)*Current CPI (Sep. 2018)
=-0.333/106.5067*106.5067
=-0.333

Current CPI (Sep. 2018) = 106.5067.

Synergy Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
200812 -0.026 88.697 -0.031
200903 -0.037 89.744 -0.044
200906 0.024 91.003 0.028
200909 0.027 91.120 0.032
200912 0.116 91.111 0.136
201003 0.089 91.821 0.103
201006 0.021 91.962 0.024
201009 -0.031 92.162 -0.036
201012 -0.067 92.474 -0.077
201103 -0.113 94.283 -0.128
201106 -0.148 95.235 -0.166
201109 -0.131 95.727 -0.146
201112 0.137 95.213 0.153
201203 0.045 96.783 0.050
201206 0.499 96.819 0.549
201209 0.374 97.633 0.408
201212 0.284 96.871 0.312
201303 0.076 98.209 0.082
201306 0.725 98.518 0.784
201309 0.612 98.790 0.660
201312 0.448 98.326 0.485
201403 0.484 99.695 0.517
201406 0.299 100.560 0.317
201409 0.155 100.428 0.164
201412 -0.043 99.070 -0.046
201503 -0.237 99.621 -0.253
201506 -0.182 100.684 -0.193
201509 -0.212 100.392 -0.225
201512 -0.446 99.792 -0.476
201603 -0.039 100.470 -0.041
201606 0.235 101.688 0.246
201609 0.060 101.861 0.063
201612 0.176 101.863 0.184
201703 0.432 102.862 0.447
201706 0.171 103.349 0.176
201709 -0.006 104.136 -0.006
201712 -0.019 104.011 -0.019
201803 -0.127 105.290 -0.128
201806 -0.223 106.317 -0.223
201809 -0.333 106.507 -0.333

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Synergy Pharmaceuticals  (FRA:S90) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Synergy Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Synergy Pharmaceuticals (FRA:S90) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170
Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines